Valeant Pharmaceuticals to launch term C and D repricing on Thursday

By Sara Rosenberg

New York, May 13 – Valeant Pharmaceuticals International Inc. is set to hold a lender call at 11 a.m. ET on Thursday to launch a repricing of an $853 million series C term loan due December 2019 and a $1,109,000,000 series D term loan due February 2019, according to a market source.

Deutsche Bank Securities Inc. and Barclays are the bookrunners on the deal.

Valeant is a Laval, Quebec-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.